PARIS, France--(BUSINESS WIRE)--Regulatory News:
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 7th Annual CEC Capital Summit.
The presentation will take place as follows:
- Date: Wednesday, September 20th, 2017
- Time: 2:50 pm PDT (11:50 pm CEST)
- Venue: Montage Beverly Hills in Beverly Hills, California
If you are interested in meeting the Pharnext management team during this event, please send an email to Matthew Shinseki at matthew@sternir.com.
About Pharnext
Pharnext is an advanced clinical-stage
biopharmaceutical company founded by renowned scientists and
entrepreneurs including Professor Daniel Cohen, a pioneer in modern
genomics. Pharnext has two lead products in clinical development.
PXT3003 is currently in an international Phase 3 trial for the treatment
of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug
status in Europe and the United States. PXT864 has generated positive
Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new
drug discovery paradigm: PLEOTHERAPY™. The Company identifies and
develops synergic combinations of repositioned drugs at new optimal
lower doses. These PLEODRUG™ offer several key advantages: efficacy,
safety and intellectual property including several product or
composition of matter patents already granted. The Company is supported
by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in
Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
